Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.55 |
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.54 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359875 | 0.88 | ALDH1A1 (0.54) | SYKIRAK4IRAK1KDM4ESMN1; SMN2 | |
| SCHEMBL19265894 | 0.87 | IRAK4 (0.52) | SYKIRAK4IRAK1NPC1RAB9A | |
| SCHEMBL359849 | 0.82 | SYK (0.62) | SYKIRAK4IRAK1 | |
| SCHEMBL15093593 | 0.82 | SYK (0.61) | SYKIRAK4IRAK1NPC1RAB9A | |
| SCHEMBL15093623 | 0.81 | SYK (0.58) | SYKIRAK4NPC1RAB9AKDM4E | |
| SCHEMBL359125 | 0.81 | SYK (0.56) | SYKIRAK4IRAK1KMT2AMAPT | |
| SCHEMBL359999 | 0.78 | NPC1 (0.54) | SYKNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL358257 | 0.78 | IRAK4 (0.70) | SYKIRAK4IRAK1NPC1RAB9A | |
| SCHEMBL358247 | 0.77 | IRAK4 (0.75) | SYKIRAK4IRAK1 | |
| SCHEMBL359660 | 0.77 | SYK (0.65) | SYKIRAK4IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | SYK 634/4885IRAK4 1/4885IRAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.